Cargando…
ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan
BACKGROUND: Early identification of autism spectrum disorder, intellectual developmental disorder, attention-deficit/hyperactivity disorder, and other neurodevelopmental disorders/problems is crucial, yet diagnosis is often delayed for years under the often misguided “wait-and-see” paradigm. The ear...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951052/ https://www.ncbi.nlm.nih.gov/pubmed/27478377 http://dx.doi.org/10.2147/NDT.S108411 |
_version_ | 1782443634340134912 |
---|---|
author | Hatakenaka, Yuhei Fernell, Elisabeth Sakaguchi, Masahiko Ninomiya, Hitoshi Fukunaga, Ichiro Gillberg, Christopher |
author_facet | Hatakenaka, Yuhei Fernell, Elisabeth Sakaguchi, Masahiko Ninomiya, Hitoshi Fukunaga, Ichiro Gillberg, Christopher |
author_sort | Hatakenaka, Yuhei |
collection | PubMed |
description | BACKGROUND: Early identification of autism spectrum disorder, intellectual developmental disorder, attention-deficit/hyperactivity disorder, and other neurodevelopmental disorders/problems is crucial, yet diagnosis is often delayed for years under the often misguided “wait-and-see” paradigm. The early symptomatic syndromes eliciting neurodevelopmental clinical examinations-questionnaire (ESSENCE-Q) is a brief (12-item) screening questionnaire developed specifically for the purpose of speeding up the identification process of a wide variety of neurodevelopmental problems. The aims were to 1) estimate the reliability of the ESSENCE-Q, 2) evaluate the clinical cutoff levels suggested by the author of the ESSENCE-Q, and 3) propose optimal cutoff levels based on receiver operating characteristic analysis. METHODS: The ESSENCE-Q was used for 1 year by a psychiatrist in Kochi, Japan, assessing children under the age of 6 years referred for developmental problems. The children were also clinically assessed with regard to whether or not they met criteria for a developmental disorder (diagnosis positive and diagnosis negative groups). We contrasted the results of the ESSENCE-Q and those of clinical diagnostic assessments in 130 cases. RESULTS: Cronbach’s alpha was 0.82, sensitivity was 0.94 (95% confidence interval [CI]: [0.88, 0.98]), and specificity 0.53 (95% CI: [0.28, 0.77]), which are reasonable psychometrics for a first-step screening tool. Based on receiver operating characteristic analysis, we recommended an optimal cutoff level of yes ≥2 or maybe/a little ≥3 on the ESSENCE-Q (0.87 (95% CI: [0.79, 0.92]) sensitivity and 0.77 (95% CI: [0.50, 0.93]) specificity). CONCLUSION AND IMPLICATION: The ESSENCE-Q can be a good instrument for use as a screening tool for aiding in the process of early identification of neurodevelopmental disorders in clinical settings. To establish the broader validity and reliability of the ESSENCE-Q, case–control studies and general population studies of children in different age groups are needed. |
format | Online Article Text |
id | pubmed-4951052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49510522016-07-29 ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan Hatakenaka, Yuhei Fernell, Elisabeth Sakaguchi, Masahiko Ninomiya, Hitoshi Fukunaga, Ichiro Gillberg, Christopher Neuropsychiatr Dis Treat Original Research BACKGROUND: Early identification of autism spectrum disorder, intellectual developmental disorder, attention-deficit/hyperactivity disorder, and other neurodevelopmental disorders/problems is crucial, yet diagnosis is often delayed for years under the often misguided “wait-and-see” paradigm. The early symptomatic syndromes eliciting neurodevelopmental clinical examinations-questionnaire (ESSENCE-Q) is a brief (12-item) screening questionnaire developed specifically for the purpose of speeding up the identification process of a wide variety of neurodevelopmental problems. The aims were to 1) estimate the reliability of the ESSENCE-Q, 2) evaluate the clinical cutoff levels suggested by the author of the ESSENCE-Q, and 3) propose optimal cutoff levels based on receiver operating characteristic analysis. METHODS: The ESSENCE-Q was used for 1 year by a psychiatrist in Kochi, Japan, assessing children under the age of 6 years referred for developmental problems. The children were also clinically assessed with regard to whether or not they met criteria for a developmental disorder (diagnosis positive and diagnosis negative groups). We contrasted the results of the ESSENCE-Q and those of clinical diagnostic assessments in 130 cases. RESULTS: Cronbach’s alpha was 0.82, sensitivity was 0.94 (95% confidence interval [CI]: [0.88, 0.98]), and specificity 0.53 (95% CI: [0.28, 0.77]), which are reasonable psychometrics for a first-step screening tool. Based on receiver operating characteristic analysis, we recommended an optimal cutoff level of yes ≥2 or maybe/a little ≥3 on the ESSENCE-Q (0.87 (95% CI: [0.79, 0.92]) sensitivity and 0.77 (95% CI: [0.50, 0.93]) specificity). CONCLUSION AND IMPLICATION: The ESSENCE-Q can be a good instrument for use as a screening tool for aiding in the process of early identification of neurodevelopmental disorders in clinical settings. To establish the broader validity and reliability of the ESSENCE-Q, case–control studies and general population studies of children in different age groups are needed. Dove Medical Press 2016-07-14 /pmc/articles/PMC4951052/ /pubmed/27478377 http://dx.doi.org/10.2147/NDT.S108411 Text en © 2016 Hatakenaka et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Hatakenaka, Yuhei Fernell, Elisabeth Sakaguchi, Masahiko Ninomiya, Hitoshi Fukunaga, Ichiro Gillberg, Christopher ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan |
title | ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan |
title_full | ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan |
title_fullStr | ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan |
title_full_unstemmed | ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan |
title_short | ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan |
title_sort | essence-q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south japan |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951052/ https://www.ncbi.nlm.nih.gov/pubmed/27478377 http://dx.doi.org/10.2147/NDT.S108411 |
work_keys_str_mv | AT hatakenakayuhei essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan AT fernellelisabeth essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan AT sakaguchimasahiko essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan AT ninomiyahitoshi essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan AT fukunagaichiro essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan AT gillbergchristopher essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan |